drugset / Trial / NCT07026968
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial to evaluate efficacy and safety of the triple combination therapy of prusogliptin, dapagliflozin and metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2026-10-30
- Completion
- 2026-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBPR108 | Small molecule | — | — |
| Subject | Dapagliflozin | Small molecule | — | — |
| Background | Metformin | Small molecule | — | — |